Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 2/20 | 0.50 |
| ▸ | EGFR | P00533 | 10/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.39 |
| ▸ | MTOR | P42345 | 4/20 | 0.39 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.39 |
| ▸ | CDK2 | P24941 | 3/20 | 0.37 |
| ▸ | JAK2 | O60674 | 2/20 | 0.37 |
| ▸ | KDR | P35968 | 2/20 | 0.37 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.37 |
| ▸ | KCNQ3 | O43525 | 2/20 | 0.36 |
| ▸ | KCNQ2 | O43526 | 2/20 | 0.36 |
| ▸ | SCD | O00767 | 1/20 | 0.36 |
| ▸ | KCNQ4 | P56696 | 1/20 | 0.36 |
| ▸ | KCNQ5 | Q9NR82 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17411280 | 0.84 | AOC3 (0.51) | AOC3EGFRPIK3CAMTORMAP4K4 | |
| SCHEMBL27773974 | 0.83 | AOC3 (0.53) | AOC3EGFRCDK2JAK2KDR | |
| SCHEMBL31195873 | 0.83 | AOC3 (0.50) | AOC3EGFRPIK3CAMTORMAP4K4 | |
| SCHEMBL31104582 | 0.83 | AOC3 (0.53) | AOC3EGFRMAP4K4CDK2JAK2 | |
| SCHEMBL12525386 | 0.82 | AOC3 (0.39) | AOC3KCNQ3KCNQ2 | |
| SCHEMBL14283205 | 0.80 | KDM4E (0.51) | AOC3EGFR | |
| SCHEMBL27855620 | 0.80 | AOC3 (0.51) | AOC3EGFRPIK3CAMTOR | |
| SCHEMBL24880754 | 0.78 | POLB (0.56) | AOC3KCNQ3KCNQ2SCDKCNQ4 | |
| SCHEMBL3828569 | 0.77 | SMO (0.42) | AOC3EGFRPIK3CAMTORCDK2 | |
| SCHEMBL20148210 | 0.76 | AOC3 (0.51) | AOC3EGFRKCNQ3KCNQ2KCNQ4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230203007-A1 | PYRIDINYLACETAMIDE DERIVATIVES AS SODIUM CHANNEL ACTIVATORS | X-CHEM GLOBAL HQ | 2023-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230203007-A1 | PYRIDINYLACETAMIDE DERIVATIVES AS SODIUM CHANNEL ACTIVATORS | SCN1A, SCN3A, SCN2A | AOC3 2605/4885EGFR 4191/4885PIK3CA 1530/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.